Want to join the conversation?
$BIIB said aducanumab, its investigational treatment for early Alzheimer's disease, was accepted into the European Medicines Agency's (EMA) PRIority MEdicines (PRIME) program. PRIME aims to bring treatments to patients faster by enhancing the EMAâ??s support for the development of investigational medicines for diseases without available treatment.
$TWTR mentions Snap as one of its fiercest rivals in its 10K filing. Great head start for Snap ahead of IPO!